Press Releases Genmab A/S

Stocks

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 11/06/2026 BST			5-day change	1st Jan Change
1,616.50 ^DKK	+0.53%		+2.08%	-20.25%

04:57pm	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-10	Nordic stocks in North America - Autoliv rose 1.6 percent	FW

Press Releases

03:46pm	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
03:45pm	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
05-29	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
05-22	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
05-21	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
05-21	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
05-13	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
05-13	Genmab A/S : has published its Articles of Association	PU
05-12	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
05-11	Genmab - Major Shareholder Announcement	AQ
05-08	Major Shareholder Announcement	GL
05-07	Genmab A/S : Investor Presentation - May 2026	PU
05-07	Genmab A/S : First Quarter 2026 Financial Results Presentation	PU
05-07	Genmab A/S : Interim Report for the First Quarter of 2026	PU
05-07	Genmab Announces Financial Results for the First Quarter of 2026	GL
05-07	Genmab Announces Financial Results for the First Quarter of 2026	AQ
04-17	Genmab A/S : has published its Articles of Association	PU
04-17	Genmab A/S Share Capital Reduction	GL
04-14	Major Shareholder Announcement	GL
04-14	Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026	GL
04-13	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer	BU
04-13	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer	GL
04-07	Genmab A/S : AGM 2026 Presentation	PU
04-01	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
04-01	Major Shareholder Announcement	GL